- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark of ALS | 96 | PR Newswire | First randomized, double-blind, placebo-controlled trial to demonstrate treatment-associated reduction of TDP-43 in people living with ALS
TDP-43 pathology is... ► Artikel lesen | |
| 25.06. | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 25.06. | NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease | 260 | PR Newswire | PrimeC was associated with changes across multiple biomarkers spanning key neurodegenerative disease pathways, providing early biological evidence consistent with... ► Artikel lesen | |
| 18.06. | Halberd Corp.: Halberd Corporation Ships Latest NeuroSense AI Version, Advancing Voice-Based Behavioral Monitoring | 3 | GlobeNewswire (USA) | ||
| 08.06. | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 24.04. | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| NEUROSENSE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 03.04. | NeuroSense Therapeutics receives Nasdaq notices over listing requirements | 20 | Seeking Alpha | ||
| 03.04. | NeuroSense Therapeutics Announces Receipt of Nasdaq Notifications Regarding Minimum Bid Price and Market Value Requirements | 265 | PR Newswire | Notifications have no immediate effect on the listing or trading of the Company's securities on Nasdaq
Nasdaq has provided the Company until September 29, 2026... ► Artikel lesen | |
| 31.03. | NeuroSense Therapeutics reports FY results, GAAP EPS of $0.44 | 2 | Seeking Alpha | ||
| 31.03. | NeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business Update | 453 | PR Newswire | 2025 marked transition of PrimeC into a late-stage clinical asset with FDA-cleared Phase 3 program in ALS
Statistically significant survival benefit demonstrated... ► Artikel lesen | |
| 31.03. | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 31.03. | NeuroSense Therapeutics Ltd. - 20-F, Annual and transition report of foreign private issuers | 2 | SEC Filings | ||
| 24.03. | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 16.03. | NeuroSense: JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity | 339 | PR Newswire | The Journal of the American Medical Association (JAMA Neurology) publication highlights consistent clinical and biomarker findings from NeuroSense PARADIGM Phase... ► Artikel lesen | |
| 11.03. | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 6 | SEC Filings | ||
| 10.03. | Roth/MKM initiates NeuroSense stock with buy on ALS drug potential | 5 | Investing.com | ||
| 18.02. | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 09.02. | Neurosense-Aktie legt nach Patent-Erfolg in Australien zu | 2 | Investing.com Deutsch | ||
| 09.02. | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 21.01. | NeuroSense granted U.S. patent for treatment of Alzheimer's disease | 9 | Seeking Alpha |
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVAVAX | 8,440 | -0,47 % | Novavax, Inc.: Novavax Reports First Quarter 2026 Financial Results and Operational Highlights | Total revenue of $140 million in the first quarter of 2026
Pfizer agreement announced in January for non-exclusive license to utilize Matrix-M® in two infectious... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 11,590 | 0,00 % | Palatin Technologies, Inc.: Palatin to Begin Trading on Nasdaq Stock Exchange | PRINCETON, N.J., May 18, 2026 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company focused on the discovery and development... ► Artikel lesen | |
| OCUGEN | 1,342 | -0,15 % | Ocugen Provides Business Update with First Quarter 2026 Financial Results | Conference Call and Webcast Today at 8:30 a.m. ET Positive 12-month data from the OCU410 Phase 2 ArMaDa clinical trial for geographic atrophy (GA) indicates a statistically significant (p About 20%... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,341 | -0,29 % | NurExone-Tochter Exo-Top ebnet Weg in den mexikanischen Exosomenmarkt | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,521 | +2,39 % | Pacific Biosciences of California (PACB) Stock Sinks As Market Gains: Here's Why | ||
| CARDIOL THERAPEUTICS | 0,930 | 0,00 % | Cardiol Therapeutics Inc.: Cardiol Therapeutics Reports Results of 2026 Annual General Meeting of Shareholders | TORONTO, June 25, 2026 /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing... ► Artikel lesen | |
| REDHILL BIOPHARMA | 0,815 | +0,34 % | RedHill Biopharma Ltd. - 6-K, Report of foreign issuer | ||
| ONCO-INNOVATIONS | 0,441 | -1,34 % | Onco-Innovations leitet Studien zur Verstoffwechselung von ONC010 in Hepatozyten und Lebermikrosomen aus drei Tierarten ein | Vancouver, Kanada - 26. Juni 2026 / IRW-Press / Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (FWB: W1H, WKN: A3EKSZ) ("Onco" oder das "Unternehmen") kündigt die Einleitung von Studien... ► Artikel lesen | |
| NOVOCURE | 14,960 | 0,00 % | Novocure to Report Second Quarter 2026 Financial Results | Novocure (NASDAQ: NVCR) will report financial results for the second quarter 2026 on July 23, 2026, before the U.S. financial markets open.
Novocure management will host a conference call and webcast... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 8,500 | +0,59 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Announces Additional Positive Week 52 Data from Landmark SOL-1 Phase 3 Trial of AXPAXLI in Wet AMD | New SOL-1 post-hoc analyses presented at VBS reinforce AXPAXLI's unmatched durability in wet AMD with sustained disease control AXPAXLI demonstrated robust CSFT control with a median time of 39 weeks... ► Artikel lesen | |
| REVOLUTION MEDICINES | 168,25 | +0,72 % | +422% in einem Jahr: Revolution Medicines nach Bauchspeicheldrüsenkrebs-Durchbruch nicht zu ... | Die Rekordfahrt bei der Aktie von Revolution Medicines hat sich zu Wochenbeginn fortgesetzt. Erstmals in der Börsengeschichte der Biotech-Gesellschaft ist der Börsenwert auf über 40 Milliarden Dollar... ► Artikel lesen | |
| ROCKET PHARMACEUTICALS | 3,300 | -2,08 % | ROCKET PHARMACEUTICALS, INC. - 8-K, Current Report | ||
| PALISADE BIO | 2,100 | 0,00 % | Palisade Bio, Inc.: Palisade Bio Receives FDA Clearance of IND for PALI-2108 and Plans to Initiate Global Phase 2 ASCENTRA-UC Study in Ulcerative Colitis | ASCENTRA-UC expected to enroll up to 204 patients with moderately to severely active ulcerative colitis across North America and Europe First patient enrollment anticipated in the second half of 2026... ► Artikel lesen | |
| ONCOLYTICS BIOTECH | 0,899 | 0,00 % | Oncolytics Biotech, Inc.: Oncolytics Biotech Announces Positive Initial Preclinical Findings Supporting Further Evaluation of Pelareorep in Combination with RAS-Targeted Approaches | SAN DIEGO, June 01, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech Inc. (Nasdaq: ONCY) ("Oncolytics" or the "Company"), a clinical-stage company developing pelareorep, today announced initial data from... ► Artikel lesen | |
| OMEROS | 8,400 | +3,45 % | Omeros Corporation Announces Update on European Marketing Authorization Application for Narsoplimab in TA-TMA | Omeros Corporation (Nasdaq: OMER) announced today an update on the review by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) of the company's marketing... ► Artikel lesen |
NEUROSENSE THERAPEUTICS LTD gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -3,48 % bei einem Aktienkurs von 0,555 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NEUROSENSE THERAPEUTICS LTD finden Sie auf Wallstreet Online.